Loading
companiesCompany
Catalent (Novo Holdings)
Catalent, of Somerset, New Jersey, is a contract manufacturer that fills and finishes sterile injectables and makes biologics and cell and gene therapies; Novo Holdings bought it in 2024 and moved three sites to Novo Nordisk. The diversion of fill-finish capacity to obesity drugs may squeeze oncology products.
Overview
Catalent, based in Somerset, New Jersey, is a fill-finish and gene therapy CDMO acquired by Novo Holdings in 2024, with three sites transferred to Novo Nordisk. It manufactures sterile injectables, biologics and cell and gene therapies, and the capacity shifts that followed the Novo deal affected some oncology sponsors. OnCo links it to sterile fill-finish and lyophilisation and to viral vector manufacturing. Whether the diversion of fill-finish capacity to obesity drugs squeezes oncology products is the open question the acquisition raised. The fill-finish technology page carries the wider picture.
Headquarters
Somerset, NJ, US
Manufacturing
Capacity map- Catalent Bloomington Bloomington, Indiana, USAntibody drug substance, Fill and finish
Type
Website
Similar pages
- CompanySamsung Biologics
Shares Sterile fill-finish and lyophilisation, GMP, inspections, Form 483s and warning letters and the tag supporting.
- CompanyOXB (Oxford Biomedica)
Shares Viral vector manufacturing (lentiviral, retroviral, AAV) and the tag supporting.
- CompanyLonza
Shares Sterile fill-finish and lyophilisation, Viral vector manufacturing (lentiviral, retroviral, AAV), GMP, inspections, Form 483s and warning letters and the tag supporting.
- CompanyCharles River Laboratories
Shares Viral vector manufacturing (lentiviral, retroviral, AAV) and the tag supporting.
- CompanyCytiva (Danaher)
Shares Viral vector manufacturing (lentiviral, retroviral, AAV) and the tag supporting.
- CompanyThermo Fisher Scientific
Shares Sterile fill-finish and lyophilisation, Viral vector manufacturing (lentiviral, retroviral, AAV) and the tag supporting.
- TechnologyGeneric oncology drug supply and shortage mitigation
Shares Sterile fill-finish and lyophilisation, GMP, inspections, Form 483s and warning letters and the tag supporting.
- TechnologyPlasmid DNA and mRNA raw-material manufacturing
Shares Viral vector manufacturing (lentiviral, retroviral, AAV) and the tag supporting.